Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, B-Cell 1

Interventions

Cyclophosphamide 21fludarabine 14Rituximab 11Immunotherapy, Adoptive 9Specimen Handling 8Vincristine 7Prednisone 7Magnetic Resonance Spectroscopy 7Doxorubicin 7Etoposide 6Biopsy 6glofitamab 5zanubrutinib 4polatuzumab vedotin 4obinutuzumab 4Lenalidomide 4Bendamustine Hydrochloride 4relmacabtagene autoleucel 3loncastuximab tesirine 3fludarabine phosphate 3axicabtagene ciloleucel 3Leukapheresis 3Ifosfamide 3Carboplatin 3tafasitamab 2etoposide phosphate 2X-Rays 2Nivolumab 2Injections 2Disulfides 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lymphoma, B-Cell × gossypol acetic acid × Clear all
NCT05338931 2022-05-26

Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

AbClon

Phase 1/2 Recruiting
82 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡